Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.
about
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathyDiabetic Cardiovascular Disease Induced by Oxidative StressCardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem CellsContractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathyHow exercise may amend metabolic disturbances in diabetic cardiomyopathyInterplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathyAntioxidant Properties of Whole Body Periodic Acceleration (pGz)Diabetic Microvascular Disease and Pulmonary Fibrosis: The Contribution of Platelets and Systemic InflammationUpdate on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseMetabolic Remodeling in Diabetic Cardiomyopathy.Diabetic cardiomyopathy: where we are and where we are going.HMGCS2 is a key ketogenic enzyme potentially involved in type 1 diabetes with high cardiovascular riskIn vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats.Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-β-D-glucoside.The role of Nrf2-mediated pathway in cardiac remodeling and heart failure.Albuminuria is associated with left ventricular hypertrophy in patients with early diabetic kidney diseaseApplication of a novel curcumin analog in the management of diabetic cardiomyopathy.Cardiac-specific suppression of NF-κB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system.Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.An altered pattern of myocardial histopathological and molecular changes underlies the different characteristics of type-1 and type-2 diabetic cardiac dysfunctionExercise ameliorates high fat diet induced cardiac dysfunction by increasing interleukin 10.Metabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome.Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling.Left ventricular diastolic dysfunction in nonhuman primate model of dysmetabolism and diabetesNaringin Reduces Hyperglycemia-Induced Cardiac Fibrosis by Relieving Oxidative StressMolecular Signature of Nitroso-Redox Balance in Idiopathic Dilated CardiomyopathiesThe soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitusCardiac fibrosis and down regulation of GLUT4 in experimental diabetic cardiomyopathy are ameliorated by chronic exposures to intermittent altitudeEarly administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagyOral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathwayMitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart DiseaseIn vivo targeted molecular magnetic resonance imaging of free radicals in diabetic cardiomyopathy within miceSerelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathwaysIn-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals.Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.Role of microRNAs in the pathogenesis of diabetic cardiomyopathy.Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Integrins and integrin-related proteins in cardiac fibrosis.Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
P2860
Q26775037-31F3E8EA-DD52-4EE7-9B2C-0871413F234BQ26778017-1CF74958-0C1F-4461-9A81-412D22B9D89CQ26798131-CB1591CD-6768-47DA-8EE7-32621E348CDFQ26799594-70467406-1F2B-4C37-9D9A-B25356C0F31DQ26863272-420CCE20-56A7-40D4-ABCF-B2D74C6D645AQ27001165-E1E075CC-0CDF-465D-9844-9CE8B92904F1Q27303654-A0444D8B-67D8-4978-9E61-1BCA4376059BQ28073977-F23A2161-F896-4E3C-AFB1-A7F24D8D6B00Q28077454-1FC6054C-8A13-498F-8627-5699520BB6A8Q33623469-1E0F8BF7-232F-4016-984E-EE9C258BF3ADQ33690717-C1360DD3-3655-4FA1-887A-E580D53EED23Q33870797-0179EFE8-346C-49E4-848A-667D0F71DAD6Q33883650-838DD78D-8F19-4234-B029-4184B1A74BE8Q33892587-F65F3734-B33D-49FC-AC1B-14645D8D2F78Q33914944-F7CC9529-FDA2-4FA2-AA5A-7A9BB3912222Q34151538-B2CFCFDC-3854-4FFC-98A3-9A5C3CDB56A1Q34227841-0AB98AFE-C1E0-4E17-B5FA-BF2C00579A9CQ34295440-80C32166-DCC5-4509-A873-F4260C6680C0Q34579301-D11C10C0-3701-49FE-9C6D-83B301ED90B3Q34989245-BAA05D5D-4C33-4C7C-91C0-205178B3D003Q35521933-E32CF8D7-F865-43AD-B70A-2A30D414293FQ35667039-CA6003C0-7B04-4C5B-B102-6A374772A65BQ35667311-3A89EB6F-A279-4979-912E-6FB50F03BB69Q35827889-0B63CA83-75C9-4CDC-BCC9-3061209B04C8Q35953912-17D1952E-9737-4EDC-90B8-949558457E7EQ36141866-FD222489-C866-40D4-B540-8439A43031D4Q36234790-B04BB7DC-0B25-4E54-B905-22CD00142870Q36785456-125D9941-8BE4-4DEF-B2E8-3842BCE011A1Q36846777-3C8A8DDE-3BE2-4951-B480-BA8F880D503CQ36875888-52C8D124-51C3-4789-B3B9-D691AA5566A0Q36877638-19496DE2-824A-4F69-AFB0-3ECED1CA9B0AQ36902956-DDD086FD-DD7E-40FF-95C1-E16301501BCDQ37571303-C0C78076-938F-4B56-A846-7E65868E6F3CQ37586770-869E4DE6-A37B-4501-BFA7-2312C6812B34Q37609947-7A2EBA55-E551-4176-872E-A1EAEA8BEE03Q37696624-672517E4-DB38-41DC-A1C7-CEE32114DE9BQ37700697-EA3A1603-9511-4311-AEF4-AB3471596C1DQ38315999-10802251-5A15-403F-92C3-81637AE16369Q38631821-3BF33DCD-51EF-452B-AB9D-C2CD6FF4B28BQ38752958-DE8B6C76-041F-42C4-86E6-8E465E3C18FB
P2860
Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Diabetic cardiomyopathy: mecha ...... ntioxidant signaling pathways.
@en
type
label
Diabetic cardiomyopathy: mecha ...... ntioxidant signaling pathways.
@en
prefLabel
Diabetic cardiomyopathy: mecha ...... ntioxidant signaling pathways.
@en
P1476
Diabetic cardiomyopathy: mecha ...... ntioxidant signaling pathways.
@en
P2093
Julie R McMullen
Karina Huynh
P304
P356
10.1016/J.PHARMTHERA.2014.01.003
P577
2014-01-22T00:00:00Z